A New Joint Scientific Statement and What to Watch for at the European Society of Cardiology Congress 2025

This week, host Craig Beavers tackles the upcoming European Society of Cardiology (ESC) Congress 2025, taking place August 29 through September 1, 2025. Key data to keep an eye on will include the following:

• The VICTORION-Difference study of inclisiran in hyperlipidemia
• The Essence study of olezarsen in hypertriglyceridemia
• Multiple studies on early discontinuation of aspirin after percutaneous coronary intervention in high-risk acute coronary syndromes
• The DAPT-SHOCK-AMI trial of cangrelor in patients with cardiogenic shock related to acute myocardial infarction
• The ALONE-AF trial about stopping anticoagulation after successful atrial fibrillation ablation
• The ODYSSEY-HCM and MAPLE-HCM studies on mavacamten and aficamten in hypertrophic cardiomyopathy

Stay tuned for upcoming episodes for deeper dives into these data and other key takeaways from ESC.